Ozanimod Hydrochloride
【Chemical Name】Ozanimod Hydrochloride
【Original】The Scripps Research Institute
【Time to market】2020.03.25
【Dosage and Usage】Capsules: 0.23 mg, 0.46 mg, 0.92 mg ozanimod. Used for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and Moderately to severely active ulcerative colitis (UC) in adults.
Ozanimod Hydrochloride
一、 Product Overview
Ozanimod Hydrochloride,developed by The Scripps Research Institute, is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and Moderately to severely active ulcerative colitis (UC) in adults.It was approved by the FDA on Mar. 25, 2020
二、Main products
Description | Structural Formula | CAS No. | Category |
 | 1306760-87-1 | API | |
(S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile hydrochloride |  | 1213099-69-4 | Intermediate |
 | 258273-31-3 | Intermediate | |
 | 86864-60-0 | Intermediate |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.